Skip to content
mapperlab
← Dashboard
Stock

BNTX

BioNTech SE
Latest close $884 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
4
27 funds tracked
Ever held
9
Current + past
New this quarter
0
Exited this quarter
1

Marquee-fund ownership over time

Aug 14, 2020Aug 14, 2023Feb 14, 2025May 15, 2026
Now
4

This quarter's activity

New positions opened

None.

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Citadel Advisors$85$88+4%
Two Sigma Investments re-entered$85$88+4%
D.E. Shaw re-entered$85$88+4%
Millennium Management re-entered$85$88+4%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Bridgewater Associates 4× in & out→ $90-15%
Viking Global Investors→ $113+9%
Point72 Asset Management→ $120+41%
Duquesne Family Office 2× in & out→ $107-0%
Coatue Management→ $108-43%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at BioNTech SE. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
6
Filings · last 90d
6
Total on file
6
Recent SEC buffer
Most recent
May 13, 2026

30d / 90d windows measured from May 13, 2026 — the most recent Form 4 on file — not from today.

Fundamentals

XBRL · BioNTech SE

Not enough XBRL history to plot. BioNTech SEhasn't tagged revenue, net income, EPS, or operating cash flow in the SEC us-gaap taxonomy with at least two fiscal-year periods — typical for SPACs / trust vehicles, pre-revenue biotechs, recent IPOs, and foreign filers reporting under IFRS.

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for BioNTech SE — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Two Sigma InvestmentsQ1 2026open$107$89-17%
D.E. ShawQ1 2026open$107$89-17%
Bridgewater AssociatesQ1 2026Q2 2026$106$90-15%
Millennium ManagementQ4 2025open$103$89-14%
Viking Global InvestorsQ4 2024Q3 2025$104$113+9%
Bridgewater AssociatesQ4 2024Q3 2025$111$113+1%
Citadel AdvisorsQ3 2024open$85$89+5%
Two Sigma InvestmentsQ3 2024Q4 2024$85$104+22%
D.E. ShawQ3 2024Q3 2025$85$113+33%
Millennium ManagementQ3 2024Q3 2025$85$113+33%
Point72 Asset ManagementQ3 2024Q1 2025$85$120+41%
Bridgewater AssociatesQ1 2024Q2 2024$91$92+1%
Duquesne Family OfficeQ2 2023Q3 2023$108$107-0%
Bridgewater AssociatesQ3 2022Q4 2022$159$157-1%
Coatue ManagementQ2 2021Q2 2023$190$108-43%
Duquesne Family OfficeQ3 2020Q4 2020$68$90+33%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.